BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2023 on Friday, February 2, 2024.

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”) today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1701 under the U.S. Application No. 16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”.

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY™ .

Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced it is expected to be added to the Nasdaq Biotechnology Index .

Halia Therapeutics today announced that the company will present at the 13th World Gastroenterology, IBD & Hepatology Conference taking place during December 15-17, 2023, in Dubai, United Arab Emirates and virtually.

Vizgen, Inc. announced that five of the ten studies published in the December 13 issue of Nature, which unveiled the first full cellular map of the adult mouse brain, leveraged MERFISH technology for spatial genomics insights.

The network adds five additional research sites, expanding its foothold across North America and its wide range of therapeutic area capabilities

Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant